At Purilogics, we take pride in designing and developing membrane chromatography technologies for biologics purification. Our mission is to provide rapid and effective purification solutions to help the biopharmaceutical industry simplify biologics purification.

Purilogics, a company recognized for its best-in-class membrane chromatography technology, development, and commercialization, is excited to announce that it has been awarded a significant grant from the National Institutes of Health (NIH) to support the research and development of first-in-market high-capacity, -selectivity, and -throughput affinity membranes for the purification of mRNA. With a grant amount of $1.7M from the Small Business Innovation Research (SBIR) program, Purilogics aims to develop mRNA affinity membranes with enabling accelerated purifications for both small and large mRNAs, as well as create and conduct field research on prototypes through industry collaboration.

Purilogics, a swiftly growing start-up noted for its novel affinity membrane chromatography technology, development, and commercialization, will be presenting their most up-to-date research on their rapid antibody and mRNA purification technologies at the 13th Annual Bioprocessing Summit.

mRNA contains specific triplets of nucleobases (codons) that encode for different amino acids for the ribosome to follow and stitch together a peptide chain that will eventually (after some modification) become a functional protein…

Antibody purification often involves the use of resin chromatogra¬phy columns for capture and polishing step purifications. However, pore diffusion of proteins is severely hindered in resins, resulting in low, flow rate-dependent capacity.

It is quite normal to see low titer recombinant protein feedstreams, such as Fc fusion protein, especially during early stage drug research and discovery. To obtain enough purified recombinant proteins, a large volume of feedstream is usually needed.

Magnetic beads are generally effective to purify antibodies at small scale, but there are quite a few scenarios that they become a detriment to your workflow, such as:…

In antibody sequencing, a small quantity of antibodies with decent purity are needed for subsequent processes. Many antibody sequencing companies also need to provide clients at least milligrams of purified antibody along with sequencing reports.…

Purilogics®’ PurexaTM-MQ multimodal anion-exchange chromatography membrane is differentiated by its high binding capacity and effectiveness in removing impurities such as host cell proteins, virus particles, DNA, and aggregates from biologic products under conditions of high solution conductivity…

Purexa™ PrA mini is designed for rapid processing of small quantity of antibodies, especially at low titers. During elution, the first 0.5 mL was discarded. As is shown in the fitures, a majority of the antibody was eluted in the second 0.5 mL elution fraction, which had a concentration of 3.3 mg/mL and was corresponding to a recovery of 78%.

Since interest is growing in the area of virus-like particles (VLPs), we would like to share some notes on what we’ve found in our research, Purilogics would like to highlight a few of our products that are well-suited for purification of VLPs…

Host cell proteins (HCPs) refer to a broad spectrum of proteins produced by the cells in which the product of interest is made. HCPs are process related impurities and are one of many critical quality attributes. Both the FDA and EMA require residual HCP to be reduced to an acceptable level.

RNases are everywhere and are difficult to completely get rid of, however managing RNAse contamination is critical to any setting in which it is paramount to maintain the integrity of RNA.1 There is plenty of instruction on general considerations.

In our second post on monoclonal antibody (mAb) aggregates, we’ve collected some more details about how and under what conditions mAbs may aggregate…

Anion-exchange chromatography (AEX) is based on coulombic interactions between biologics and the purification media.

Vaccines are prophylactics designed to safely introduce epitopes of bacteria or viruses to your immune system to stimulate a response unique to the antigen…

The presence of aggregates in therapeutic monoclonal antibody (mAb) drugs is a major concern because they can decrease product efficacy and cause an immunogenic response in patients…

Purilogics® develops novel membrane adsorbers for biologics purification. Unlike other high capacity membrane products, PurexaTM membrane products are differentiated by their tentacle based ion-exchange ligands.

PurexaTM-DMAE is Purilogics’ line of dimethylaminoethyl-based, weak anion-exchange membrane chromatography products.

It is the highest capacity weak anion-exchange membrane chromatography product line commercially available.

As part of the Small Business Innovative Research (SBIR) program, the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Purilogics with a grant to commercialize affinity membrane adsorbers for purification of influenza vaccines.